From steroid dependence to molecular precision, the Graves’ orbitopathy treatment is undergoing a seismic shift. But can innovation keep pace with the burden of disease?
From Desperation to Discovery
For decades, Graves’ orbitopathy stood as one of medicine’s most frustrating autoimmune disorders. The condition, triggered by misguided immune attacks on the tissues around the eyes, left patients with a cruel spectrum of symptoms — bulging eyes, double vision, chronic pain, and, in some cases, permanent loss of sight.
Physicians had few tools. High-dose corticosteroids were the default weapon, able to dampen inflammation but notorious for their bluntness:...
